Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Dose Strengths of Selexipag in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion Criteria:~* Male subjects aged from 18 to 45 years (inclusive) at screening~* Signed informed consent form~* Body mass index (BMI) between 18.0 and 28.0 kg/m2 (inclusive) at screening~* Healthy on the basis of physical examination,cardiovascular assessments and laboratory tests~Key exclusion Criteria:~* Any contraindication to the study treatments~* History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments~* Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Sequence AB (Type: EXPERIMENTAL): Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
- Sequence BA (Type: EXPERIMENTAL): Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).